hNPC01 Injection

About Hopstem Biotechnology

Hopstem Biotechnology is a pioneering cell therapy company leveraging human iPSC technology to create neural progenitor cells for treating central nervous system injuries and diseases. The company has achieved significant regulatory milestones, with its lead candidate, hNPC01, receiving clinical trial approvals from both the U.S. FDA and China's CFDA (now NMPA) for chronic stroke hemiplegia, and a recent FDA Fast Track Designation. Operating as a private, pre-revenue entity, Hopstem is positioned at the forefront of a rapidly evolving field, aiming to address a substantial unmet medical need in neuroregeneration with its scalable platform.

Therapeutic Areas